LPAM
LENZ

Lodestar Private Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Lodestar Private Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,028
Closed -$47.1K – 197
2022
Q4 		$47.1K Buy
+2,028
New +$47K 0.01% 189

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lodestar Private Asset Management's LENZ Position: Q1 2023 in Review

Lodestar Private Asset Management sold out of LENZ Therapeutics (LENZ) in Q1 2023, closing a stake of 2,028 shares — an estimated $47.1K sold.

Lodestar Private Asset Management first reported a position in LENZ in Q4 2022 and held it in 1 quarter. The position peaked at $47.1K in Q4 2022. 62 funds tracked by Wall St. Rank hold LENZ as of Q1 2023.

  • Lodestar Private Asset Management reported no remaining LENZ Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Lodestar Private Asset Management sold 2,028 LENZ Therapeutics shares in Q1 2023, an estimated $47.1K.
  • Lodestar Private Asset Management first reported a position in LENZ Therapeutics in Q4 2022 and held it in 1 quarter.
  • Lodestar Private Asset Management's LENZ Therapeutics position peaked at $47.1K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2023.

Based on Lodestar Private Asset Management's 13F filing for Q1 2023, filed 25 Apr 2023.